For research use only. Not for therapeutic Use.
Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts[1][2][3].
Crisnatol (1.3 μg/mL; 24-72 h) inhibits the replication of HepG2 cells, decreases cell viability by 35%[2].
Crisnatol (25 mg/kg; p.o.; single dose) shows oral activity and shows stable metabolite profile extract of rat feces by autoradiography[2].
| Catalog Number | I025203 |
| CAS Number | 96389-68-3 |
| Synonyms | 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol |
| Molecular Formula | C23H23NO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H23NO2/c1-23(14-25,15-26)24-13-17-12-22-18-7-3-2-6-16(18)10-11-21(22)20-9-5-4-8-19(17)20/h2-12,24-26H,13-15H2,1H3 |
| InChIKey | SBRXTSOCZITGQG-UHFFFAOYSA-N |
| SMILES | CC(CO)(CO)NCC1=CC2=C(C=CC3=CC=CC=C32)C4=CC=CC=C41 |
| Reference | [1]. Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res. 1989 Dec 1;49(23):6615-20. [2]. Patel DK, et al. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem Pharmacol. 1991 Jul 5;42(2):337-46. [3]. Patel DK, et al. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. Drug Metab Dispos. 1991 Mar-Apr;19(2):491-7. |
